Tekla Capital Management LLC Hille Vax, Inc. Put Options Transaction History
Tekla Capital Management LLC
- $2.53 Billion
- Q2 2023
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding HLVX
# of Institutions
82Shares Held
39MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.78MShares$141 Million8.54% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4MShares$57.7 Million1.38% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.06MShares$44.1 Million0.03% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.57MShares$37.1 Million1.41% of portfolio
-
Vr Adviser, LLC New York, NY2.08MShares$29.9 Million2.96% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $482M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.